Please assess the completion status of the following clinical trial:

Trial Title: S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* At elevated risk of developing breast cancer, as defined by 1 of the following:~  * Modified Gail risk at 5 years ≥ 1.7% or lifetime risk ≥ 20% AND Claus Model, BRCAPro Model, or Tyrer-Cuzick Model lifetime risk ≥ 20%~ * Diagnosis of lobular carcinoma in situ or ductal carcinoma in situ~ * Known deleterious mutation of BRCA1 or BRCA2~* At least 1 breast available for imagery and biopsy~* Has undergone a baseline mammogram with a standard density wedge within 7-14 days after completion of the last menstrual period AND within 7 days before study entry~  * Mammogram normal or benign (BIRADS score 0 or 1)~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female~Menopausal status~* Premenopausal, defined by 1 of the following criteria:~  * Last menstrual period \< 6 months ago AND no prior bilateral ovariectomy AND not on estrogen replacement therapy~ * Prior hysterectomy (with ovaries still in place) AND normal follicle-stimulating hormone levels within 28 days of study entry~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Bilirubin \< 2.0 times institutional upper limit of normal (IULN)~* SGOT or SGPT \< 2 times IULN~* Alkaline phosphatase \< 2 times IULN~* INR ≤ 1.5~* PT and PTT ≤ IULN~Renal~* Serum creatinine \< 2.0 times IULN~Cardiovascular~* No history of myocardial infarction~* No angina pectoris~* No known coronary artery disease~* No history of stroke or mini-stroke (e.g., transient ischemic attack)~* No history of thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism)~* No uncontrolled hypertension (i.e., blood pressure \> 140/90 mmHg)~Pulmonary~* No asthma after taking aspirin or other NSAIDs~Other~* No known sensitivity to celecoxib~* No allergy to sulfonamides~* No urticaria or allergic-type reactions after taking aspirin or other NSAIDs~* No extreme lactose intolerance~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or early bladder cancer (preinvasive transitional cell carcinoma of the bladder)~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 5 years since prior biologic therapy for cancer~Chemotherapy~* More than 5 years since prior chemotherapy for cancer~Endocrine therapy~* At least 28 days since prior tamoxifen~* No prior systemic estrogen modifiers (SERMs) or aromatase inhibitors~* Concurrent hormonal contraception (i.e., pills, patches, or shots) allowed provided contraception was initiated prior to study entry~Radiotherapy~* No prior radiotherapy to the breast to be studied~Surgery~* Not specified~Other~* At least 7 days since prior anticoagulant therapy~* More than 1 month since prior chronic daily aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) of more than 7 days duration~  * Concurrent intermittent aspirin or NSAIDs allowed (no more than 10 days per month)~* No concurrent participation in another clinical trial for treatment or prevention of cancer unless no longer receiving treatment and is in the follow-up phase

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I - Celecoxib (Type: EXPERIMENTAL): Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
- Arm II - Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).